Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890953113> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2890953113 endingPage "e23510" @default.
- W2890953113 startingPage "e23510" @default.
- W2890953113 abstract "e23510 Background: Accumulating evidence suggests that patients with high-risk gastrointestinal stromal tumor (GIST) can significantly benefit from adjuvant therapy with imatinib. However, the effect of this therapy in intermediate-risk GIST patients, particularly within gastric, has yet to be well demonstrated. Herein, we explored the efficacy of adjuvant imatinib in patients with gastric intermediate-risk GIST (GIGIST). Methods: The clinicopathologic and follow-up data on 93 GIGIST cases diagnosed from January 2005 to December 2016 at Union Hospital, Wuhan China were analyzed retrospectively. Univariate and multivariate analyses were performed to assess the prognostic factors for GIGIST. The patients were divided into three subgroups (Table) according to the multivariate analysis results to evaluate the efficacy of adjuvant imatinib. Results: We examined 43 male and 50 female patients with a median age of 60 years (range, 21-84 years). All patients underwent complete resection, and 42 (45%) patients were prescribed adjuvant imatinib 400 mg/day after surgery. The median adjuvant therapy period was 16 months (range, 12-72 months). The majority of the patients (86% [n = 80]) underwent followed-up for a median period of 46 months (range, 6-120 months). The 1-, 3-, and 5-year recurrence-free survival (RFS) rates in the whole group were 100.0%, 91.5% and 88.5%, respectively. Multivariate analysis revealed that the mitotic count (P = 0.040, relative risk (RR) = 6.078 [95% confidence interval (CI), 0.541-68.274]) and neutrophil-lymphocyte ratio (NLR; P = 0.036, RR = 6.102 [95% CI 0.782-47.632]) were prognostic risk factors for RFS. Adjuvant imatinib markedly increased the RFS rates in patients with a mitotic count greater than 2/50 high-power fields (HPF) and an NLR greater than 2.3 but not in the other two subgroups. Conclusions: GIGIST has a favorable overall prognosis. Patients with a mitotic count greater than 2/50 HPF and an NLR greater than 2.3 were identified as an advantageous group for adjuvant imatinib and targeted therapy longer than 1 year is strongly recommended to increase the RFS rate. Subgroup Mitotic count NLR Number of patients 1 ≤2 HPF Any value 28 2 > 2 to ≤10 HPF ≤2.3 28 3 > 2 to ≤10 HPF > 2.3 24" @default.
- W2890953113 created "2018-09-27" @default.
- W2890953113 creator A5015709922 @default.
- W2890953113 creator A5029360035 @default.
- W2890953113 creator A5030719289 @default.
- W2890953113 creator A5039207540 @default.
- W2890953113 creator A5043543046 @default.
- W2890953113 creator A5062115626 @default.
- W2890953113 creator A5067612393 @default.
- W2890953113 date "2018-05-20" @default.
- W2890953113 modified "2023-10-18" @default.
- W2890953113 title "Efficacy analysis of adjuvant therapy with imatinib for gastric intermediate-risk gastrointestinal stromal tumor." @default.
- W2890953113 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.e23510" @default.
- W2890953113 hasPublicationYear "2018" @default.
- W2890953113 type Work @default.
- W2890953113 sameAs 2890953113 @default.
- W2890953113 citedByCount "0" @default.
- W2890953113 crossrefType "journal-article" @default.
- W2890953113 hasAuthorship W2890953113A5015709922 @default.
- W2890953113 hasAuthorship W2890953113A5029360035 @default.
- W2890953113 hasAuthorship W2890953113A5030719289 @default.
- W2890953113 hasAuthorship W2890953113A5039207540 @default.
- W2890953113 hasAuthorship W2890953113A5043543046 @default.
- W2890953113 hasAuthorship W2890953113A5062115626 @default.
- W2890953113 hasAuthorship W2890953113A5067612393 @default.
- W2890953113 hasConcept C121608353 @default.
- W2890953113 hasConcept C126322002 @default.
- W2890953113 hasConcept C141071460 @default.
- W2890953113 hasConcept C143998085 @default.
- W2890953113 hasConcept C144301174 @default.
- W2890953113 hasConcept C16930146 @default.
- W2890953113 hasConcept C2775922572 @default.
- W2890953113 hasConcept C2777007597 @default.
- W2890953113 hasConcept C2777583451 @default.
- W2890953113 hasConcept C2777863537 @default.
- W2890953113 hasConcept C2777982462 @default.
- W2890953113 hasConcept C2778729363 @default.
- W2890953113 hasConcept C3019892230 @default.
- W2890953113 hasConcept C38180746 @default.
- W2890953113 hasConcept C44249647 @default.
- W2890953113 hasConcept C71924100 @default.
- W2890953113 hasConcept C82789193 @default.
- W2890953113 hasConcept C90924648 @default.
- W2890953113 hasConceptScore W2890953113C121608353 @default.
- W2890953113 hasConceptScore W2890953113C126322002 @default.
- W2890953113 hasConceptScore W2890953113C141071460 @default.
- W2890953113 hasConceptScore W2890953113C143998085 @default.
- W2890953113 hasConceptScore W2890953113C144301174 @default.
- W2890953113 hasConceptScore W2890953113C16930146 @default.
- W2890953113 hasConceptScore W2890953113C2775922572 @default.
- W2890953113 hasConceptScore W2890953113C2777007597 @default.
- W2890953113 hasConceptScore W2890953113C2777583451 @default.
- W2890953113 hasConceptScore W2890953113C2777863537 @default.
- W2890953113 hasConceptScore W2890953113C2777982462 @default.
- W2890953113 hasConceptScore W2890953113C2778729363 @default.
- W2890953113 hasConceptScore W2890953113C3019892230 @default.
- W2890953113 hasConceptScore W2890953113C38180746 @default.
- W2890953113 hasConceptScore W2890953113C44249647 @default.
- W2890953113 hasConceptScore W2890953113C71924100 @default.
- W2890953113 hasConceptScore W2890953113C82789193 @default.
- W2890953113 hasConceptScore W2890953113C90924648 @default.
- W2890953113 hasIssue "15_suppl" @default.
- W2890953113 hasLocation W28909531131 @default.
- W2890953113 hasOpenAccess W2890953113 @default.
- W2890953113 hasPrimaryLocation W28909531131 @default.
- W2890953113 hasRelatedWork W143397309 @default.
- W2890953113 hasRelatedWork W1482073432 @default.
- W2890953113 hasRelatedWork W1550269226 @default.
- W2890953113 hasRelatedWork W2017954248 @default.
- W2890953113 hasRelatedWork W2018840920 @default.
- W2890953113 hasRelatedWork W2223383871 @default.
- W2890953113 hasRelatedWork W2275018367 @default.
- W2890953113 hasRelatedWork W2357324350 @default.
- W2890953113 hasRelatedWork W2563438673 @default.
- W2890953113 hasRelatedWork W3117440509 @default.
- W2890953113 hasVolume "36" @default.
- W2890953113 isParatext "false" @default.
- W2890953113 isRetracted "false" @default.
- W2890953113 magId "2890953113" @default.
- W2890953113 workType "article" @default.